Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.

 

 

2017

Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics
Nerina Coppini, 8 June 2017

Provides range of discovery, CMC and non-clinical services Greenwich, CT, June 8, 2017 - Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc (Nasdaq:RGLS), an innovative biopharmaceutical company. The agreement includes a...

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter
Nerina Coppini, 23 May 2017

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance
Nerina Coppini, 19 April 2017

Read the article on antimicrobial resistance from our very own Antonio Felici, which was published in Bioscience Technology this month. Read full article from Bioscience Technology online site

Pharma's Almanac on Aptuit's Collaboration with Bioversys
Nerina Coppini, 6 April 2017

Nice coverage in Pharma's Almanac of Aptuit's collaboration with Bioversys. Aptuit in Bacteria Resistance Collaboration Drug development firm Aptuit has begun a joint collaboration with the Swiss biotech Bioversys that is aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. The partners hope...

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens
Nerina Coppini, 7 March 2017

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious...

Dementia Discovery Fund Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes
Nerina Coppini, 28 February 2017

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter into a strategic partnership to leverage the DDF library and Aptuit’s capabilities for dementia drug discovery London, Boston, Greenwich - February 28, 2017 – The Dementia Discovery Fund (‘DDF’), a venture...

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership
Nerina Coppini, 7 February 2017

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s unique label-free platform as well as Aptuit’s broad...

Aptuit announces drug discovery collaboration with Massachusetts General Hospital (MGH) to identify novel treatments for Gram-negative infections
Nerina Coppini, 24 January 2017

Greenwich, CT - January 24, 2017 - Aptuit, LLC today announced the start of a collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH), directed by Dr. Laurence Rahme, aimed at the identification and validation of novel targets in Gram-negative bacteria. Aptuit hopes that innovative approaches can address...

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis
Nerina Coppini, 4 January 2017

Greenwich, CT, and Parma, Italy – January 4, 2017 Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing...

 

 

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308